Skip to main content

Advertisement

Table 1 Baseline characteristics of patients with metastatic colorectal cancer (mCRC) who were treated with famitinib or placebo in the full analysis set

From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial

Characteristic Whole cohort Famitinib group Placebo group P value
Total (cases) 154 99 55  
Age (years) 0.352
 Mean ± SD 54.1 ± 9.5 54.7 ± 9.9 53.2 ± 8.8  
 Median (range) 55 (24–71) 55 (24–70) 54 (32–71)  
Age group [cases (%)] 0.437
 > 60 years 106 (68.8) 66 (66.7) 40 (72.7)  
 ≤ 60 years 48 (31.2) 33 (33.3) 15 (27.3)  
Gender [cases (%)] 0.679
 Male 89 (57.8) 56 (56.6) 33 (60.0)  
 Female 65 (42.2) 43 (43.4) 22 (40.0)  
ECOG performance status [cases (%)] 0.776
 0 27 (17.5) 18 (18.2) 9 (16.4)  
 1 127 (82.5) 81 (81.8) 46 (83.6)  
LDH level [cases (%)] 0.663
 ≤ 1.5 × ULN 126 (81.8) 80 (80.8) 46 (83.6)  
 > 1.5 × ULN 28 (18.2) 19 (19.2) 9 (16.4)  
Number of metastatic organs [cases (%)] 0.499
 ≤ 2 84 (54.5) 56 (56.6) 28 (50.9)  
 > 2 70 (45.5) 43 (43.4) 27 (49.1)  
Primary site of disease [cases (%)] 0.485
 Rectum 73 (47.4) 49 (49.5) 24 (43.6)  
 Colon 81 (52.6) 50 (50.5) 31 (56.4)  
History of primary tumor resection [cases (%)] 0.559
 No 14 (9.1) 10 (10.1) 4 (7.3)  
 Yes 140 (90.9) 89 (89.9) 51 (92.7)  
History of anti-tumor monoclonal antibody therapy [cases (%)] 0.579
 No 83 (53.9) 55 (55.6) 28 (50.9)  
 Yes 71 (46.1) 44 (44.4) 27 (49.1)  
Famitinib treatment as [cases (%)] 0.622
 Third-line therapy 60 (39.0) 40 (40.4) 20 (36.4)  
 > Third-line therapy 94 (61.0) 59 (59.6) 35 (63.6)  
White blood cell count (109/L) 0.646
 Mean ± SD 6.6 ± 2.5 6.7 ± 2.4 6.5 ± 2.7  
 Median (range) 6.1 (3.0–17.0) 6.2 (3.0–15.0) 5.8 (3.0–17.0)  
Alkaline phosphatase (U/L) 0.887
 Mean ± SD 127.3 ± 82.8 126.6 ± 82.6 128.6 ± 84.0  
 Median (range) 104.0 (26.0–580.0) 105.0 (26.0–580.0) 103.0 (46.0–458.0)  
  1. SD standard deviation, ECOG Eastern Cooperative Oncology Group, LDH lactate dehydrogenase, ULN upper limit of normal